THE ROLE OF BETA-BLOCKERS IN THE TREATMENT OF CARDIOVASCULAR DISEASES IN PREGNANT WOMEN
https://doi.org/10.20996/1819-6446-2012-8-5-699-702
Abstract
Highly selective β-adrenoblockers (β-AB) are used in pregnant women with cardiovascular diseases (arterial hypertension, arrhythmia, Marfan syndrome, hypertrophic cardiomyopathy). β-AB fall into the category C according to safety classification of Food and Drug Administration (US FDA). Their prescription in different clinical situations meets the principle of "risk–benefit". Fetus and newborn status should be monitored because β-AB can cause bradycardia, hypoglycemia, apnea and metabolic disorders. The risk of these side effects is extremely low, while β-AB clinical efficacy is high.
About the Authors
R. I. Striuk
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
Russian Federation
Russian Federation
Ya. V. Brytkova
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
Russian Federation
Russian Federation
References
1. The health status of pregnancy, labor, childbirth and newborns. Rosstat; 2012. Available at: http://www.gks.ru/free_doc/new_site/population/zdrav/zdr3–2.xls. Date of access: 10/25/2012. Russian (Состояние здоровья беременных, рожениц, родильниц и новорожденных. Росстат; 2012. Доступно на: http://www.gks.ru/free_doc/new_site/population/zdrav/zdr3–2.xls. Дата доступа:25.10.2012).
2. Weiss B.M., von Segesser L.K., Alon E., et al. Outcome of cardiovascular surgery and pregnancy: a systematic review of the period 1984–1996. Am J Obstet Gynecol 1998;179:1643–1653.
3. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011;32(24):3147–97.
4. Briggs G. G., Freeman R. K., Yaffe S. J. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Philadelphia: Lippincott Williams and Wilkins; 2005.
5. Kulakov V.I. Reproductive health of the Russian population. Akusherstvo i Ginekologiya 1998; (5): 3–
6. Russian (Кулаков В.И. Репродуктивное здоровье населения России. Акушерство и Гинекология 1998; (5): 3–6).
7. James P.R., Nelson-Piercy C. Management of hypertension before, during, and after pregnancy. Heart 2004;90:1499–1504.
8. Madi J.M., Araújo B.F., Zatti H., et al. Chronic hypertension and pregnancy at a tertiary-care and university hospital. Hypertens Pregnancy 2012;31(3):350–6.
9. National guidelines for the diagnosis and treatment of heart disease in pregnancy. Kardiovaskulyarnaya Terapiya i Profilaktika 2010; 9(6), suppl 2: 1–38. Russian (Национальные рекомендации по диагностике и лечению сердечно-сосудистых заболеваний при беременности. Кардиоваскулярная терапия и профилактика 2010; 9(6), Приложение 2: 1–38).
10. Abalos E., Duley L., Steyn D.W., Henderson-Smart D.J. Cochrane Database Syst Rev 2007; (1): CD002252.
11. Magee L.A., Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2003; (3): CD002863.
12. Striuk R.I., Brytkova Ia.V., Bukhonkina Iu.M., Pavlova L.N. Clinical efficacy of antihypertensive therapy of pregnant women with arterial hypertension with long acting nifedipine and bisoprolol. Kardiologiia. 2008;48(4):29–33. Russian (Стрюк Р.И., Брыткова Я.В., Немировский В.Б., Павлова Л.Н., Бухонкина Ю.М. Клиническая эффективность антигипертензивной терапии нифедипином пролонгировванного действия и бисопрололом беременных с артериальной гипертонией. Кардиология 2008; 48(4); 29–33).
13. Striuk R.I., Brytkova Ya.V., Nemirovskiy V.B., et al. Perinatal outcomes in pregnant women with hypertension, prolonged corrected by nifedipine and bisoprolol. Atmosfera (Novosti Kardiologii) 2012;(1):15–19. Russian (Стрюк Р.И., Брыткова Я.В., Немировский В.Б., и др. Перинатальные исходы у беременных с артериальной гипертонией, корригированной пролонгированным нифедипином и бисопрололом. Атмосфера (Новости Кардиологии) 2012;(1):15–19).
14. Silversides C.K., Harris L., Haberer K., et al. Recurrence rates of arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and neonatal outcomes. Am J Cardiol 2006;97(8):1206–1212
15. Striuk R.I., Bukhonkina Yu.M., Brytkova Ya.V., Shoikiemova D.U. Cardiac arrhythmias in pregnancy. Effektivnaya Farmakoterapiya v Kardiologii i Angiologii 2008;(1);42–46. Russian (Стрюк Р.И., Бухонкина Ю.М., Брыткова Я.В.. Шоикиемова Д.У. Нарушения сердечного ритма при беременности. Эффективная Фармакотерапия в Кардиологии и Ангиологии 2008;(1);42–46).
16. Rashba E.J., Zareba W., Moss A.J., et al. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. LQTS Investigators. Circulation 1998;97:451–456.
17. Spirito P., Autore C. Management of hypertrophic cardiomyopathy. BMJ 2006;332: 1251–1255.
Review
For citations:
Striuk R.I., Brytkova Y.V. THE ROLE OF BETA-BLOCKERS IN THE TREATMENT OF CARDIOVASCULAR DISEASES IN PREGNANT WOMEN. Rational Pharmacotherapy in Cardiology. 2012;8(5):699-702. (In Russ.) https://doi.org/10.20996/1819-6446-2012-8-5-699-702
Views: 562
Email this article 